Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 13, 2002, Pages 5-11

  Nemeroff, Charles B ^a   Kinkead, Becky ^a   Goldstein, Jeffrey ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE; DOPAMINE 2 RECEPTOR; HISTAMINE; NEUROTENSIN; NEUROTRANSMITTER RECEPTOR; PROLACTIN; QUETIAPINE; SEROTONIN;

ARTICLE; BRAIN; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC SYSTEM; LIVER METABOLISM; NEUROPROTECTION; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIBENZOTHIAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; GENE EXPRESSION; GENES, IMMEDIATE-EARLY; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, NEUROTRANSMITTER; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036459983     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Goldstein J. Preclinical profile of Seroquel (quetiapine): An atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwen GW, eds. Schizophrenia: Breaking Down the Barriers. New York, NY: John Wiley & Sons; 1996:177-208
2. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci 2000;68:29-39
3. Migler BM, Warawa EJ, Malick JB. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology (Berl) 1993;112:299-307
4. Goldstein J. Quetiapine fumarate (seroquel): A new atypical antipsychotic. Drugs Today 1999;35:193-210
5. Swerdlow NR, Zisook D, Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharmacology (Berl) 1994;114:675-678
6. Swerdlow NR, Bakshi V, Geyer MA. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 1996;279: 1290-1299
7. Swerdlow NR, Bakshi V, Waikar M, et al. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology (Berl) 1998;140:75-80
8. Bakshi VP, Swerdlow NR, Braff DL, et al. Reversal of isolation rearing-induced deficits in prepulse inhibition by Seroquel and olanzapine. Biol Psychiatry 1998;43:436-445
9. Binder EB, Kinkead B, Owens MJ, et al. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: Evidence from animal models of sensorimotor gating. J Neurosci 2001;21:601-608
10. Ellenbroek BA, Lubbers LJ, Cools AR. Activity of "Seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine. Neuropsychopharmacology 1996;15: 406-416
11. Goldstein JM, Litwin LC, Sutton EB, et al. Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:293-298
12. Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000;31:302-312
13. Binder EB, Kinkead B, Owens MJ, et al. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001;50:856-872
14. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002;42:165-179
15. Carlsson A, Waters N, Holm-Waters S, et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 2001;41:237-260
16. Seeman P, Van Tol HH. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-270
17. Langer DH, Brown GL, Docherty JP. Dopamine receptor supersensitivity and schizophrenia: A review. Schizophr Bull 1981;7:208-224
18. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711-717
19. Kinkead B, Nemeroff CB. Neurotensin: An endogenous antipsychotic? Curr Opin Pharmacol 2002;2:99-103
20. Kinkead B, Binder EB, Nemeroff CB. Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry 1999;46:340-351
21. Hamid EH, Hyde TM, Egan MF, et al. Neurotensin receptor binding abnormalities in the entorhinal cortex in schizophrenia and affective disorders. Biol Psychiatry 2002;51:795-800
22. Govoni S, Hong JS, Yang HY, et al. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J Pharmacol Exp Ther 1980;215: 413-417
23. Kilts CD, Anderson CM, Bissette G, et al. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol 1988;37:1547-1554
24. Merchant KM, Dobner PR, Dorsa DM. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci 1992;12:652-663
25. Radke JM, Owens MJ, Ritchie JC, et al. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc Natl Acad Sci U S A 1998;95:11462-11464
26. Kinkead B, Shahid S, Owens MJ, et al. Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain. J Pharmacol Exp Ther 2000;295:67-73
27. Dragunow M, Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 1989;29:261-265
28. Dragunow M, Robertson GS, Faull RL, et al. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287-294
29. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-1066
30. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377
31. Meador-Woodruff JH, Healy DJ. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 2000;31:288-294
32. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007
33. Tascedda F, Lovati E, Blom JM, et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (quetiapine fumarate). Neuropsychopharmacology 1999;21:211-217
34. Takahashi M, Shirakawa O, Toyooka K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000;5:293-300
35. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999;20: 59-61
36. Phillips HS, Hains JM, Laramee GR, et al. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons. Science 1990;250:290-294
37. Harrison PJ. The neuropathology of schizophrenia: A critical review of the data and their interpretation. Brain 1999;122:593-624
38. Arango C, Kirkpatrick B, Koenig J. At issue: Stress, hippocampal neuronal turnover, and neuropsychiatric disorders. Schizophr Bull 2001;27:477-480
39. Gispen-de Wied CC. Stress in schizophrenia: An integrative view. Eur J Pharmacol 2000;405:375-384
40. Xu H, Qing H, Lu W, et al. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci Lett 2002;321:65-68
41. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 2001;40:509-522
42. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61:252-260
43. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:521-533
44. Potkin SG, Thyrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-130
45. Potkin SG, Thyrum PT, Alva G, et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002;22:174-182
46. Potkin S, Thyrum P, Bera R, et al. Pharmacokinetics and safety of lithium coadministered with Seroquel (quetiapine) [abstract]. Schizophr Res 1997; 24:199
47. Strakowski SM, Keck PE Jr, Wong YW, et al. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol 2002;22: 201-205
48. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21:89-93
49. Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin Ther 2002;24:209-222
50. Gefvert O, Bergstrom M, Langstrom B, et al. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119-126
51. Goldstein J, Chengappa KR, Parepally H, et al. A random-assignment, double-blind, clinical trial of once- versus twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2001; Waikoloa, Hawaii
52. Thyrum PR, Yeh C, Potkin SG, et al. Safety and tolerability of switching from conventional antipsychotic therapy to Seroquel (quetiapine fumarate) followed by withdrawal from Seroquel. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Waikoloa, Hawaii
53. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
54. Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001;11:105-110
55. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 1997;133:323-328
56. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559
57. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-134
58. Stephenson CM, Bigliani V, Jones HM, et al. Striatal and extrastriatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo: [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 2000;177:408-415
59. Jones HM, Travis MJ, Mulligan R, et al. In vivo 5-HT2A receptor blockade by quetiapine: An R91150 single photon emission tomography study. Psychopharmacology (Berl) 2001;157:60-66